Nature Neuropsychopharmacology October 2024 Nature Neuropsychopharmacology: PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
Springer Nature Psychopharmacology July 2022 A randomized, double‑blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB‑102